The Cytokine Release Syndrome Management Market Size is valued at USD 23.1 billion in 2023 and is predicted to reach USD 36.8 billion by the year 2031 at a 6.2% CAGR during the forecast period for 2024-2031.
Management of Cytokine Release Syndrome (CRS) entails regulating a severe immune response that may arise during treatments such as CAR T-cell therapy. Hence, the adoption of Cytokine Release Syndrome Management is expected to increase in the near future as concerns grow over the treatment and technological advancement. Growing adoption of Cytokine release syndrome management due to an increase in the prevalence of the disease and a rise in healthcare expenses are factors expected to drive the growth of the global Cytokine Release Syndrome Management market. Additionally, technological advancement and modernization in the healthcare sector and the rising demand from developing economies in various industries are some of the other factors expected to augment the target market growth. The increasing number of the aged population globally is expected to boost the market expansion in the coming years.
However, the high cost of Cytokine Release Syndrome Management and ineffective treatment, coupled with the COVID-19 outbreak, are factors that may affect the growth of the target market during the forecast period. Furthermore, increasing R&D activities, government initiatives and promotions to use sustainable components for production, and investments by key players are factors expected to create lucrative development opportunities in terms of revenue for players operating in the global Cytokine Release Syndrome Management market over the forecast period.
Competitive Landscape
Some Major Key Players In The Cytokine Release Syndrome Management Market:
- Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc
- Novartis AG
- Sanofi S.A
- Pfizer Inc.
- Bayer AG
- Biocon
- AbbVie Inc.
- Johnson & Johnson Private Limited
- Incyte Corporation
- Swedish Orphan Biovitrum
- Genentech
- Other Market Players
Market Segmentation:
The Cytokine Release Syndrome Management market is segmented on the basis of cytokine type, therapeutic application, biomarker type, route of administration, and end user. Based on cytokine type, the market is segmented as Tumor Necrosis Factor-TNF, Interleukins-II, Interfernos-IFN, and Epidermal Growth Faator-EGF. As per the Therapeutic application, the market is segmented into Cancer, Asthma, Airway Inflammation, Arthritis, and Others. The Biomarker Type segment includes Interleukin-10, Interferon Gamma, Interleukin-6, Ferritin, and Cluster of Differentiation-163. The Route of Administration segment consists of Oral and Intravenous. By End User, the market is segmented into Hospitals, Specialty Clinics, and Others.
Based On Cytokine Type, The Tumour Necrosis Factor-TNF Segment Is Accounted As A Major Contributor In The Cytokine Release Syndrome Management Market
The Tumor Necrosis Factor-TNF category is expected to hold a major share in the global Cytokine Release Syndrome Management market in 2023. This is attributed to growing new technologies and rising awareness. The usage of therapy is rising as a direct result of cytokine release syndrome, which is an adverse reaction linked with cancer treatments.
The Arthritis Therapeutics Segment Witnessed Rapid Growth.
The arthritis therapeutics segment is projected to grow at a rapid rate in the global Cytokine Release Syndrome Management market owing to the growing aged population. Hence, the increasing aging population with lifestyle factors like obesity and sedentary habits contributes to the rising incidence of arthritis globally.
In The Region, The North American Cytokine Release Syndrome Management Market Holds A Significant Revenue Share.
The North American cytokine release syndrome management market is expected to record the very large market revenue share in the near future. This can be attributed to the rising cancer cases and other chronic diseases in the region, with the increasing adoption of Cytokine Release Syndrome Management for the treatment. In addition, small-molecule drugs and novel monoclonal antibodies in the region focus on the adoption of Cytokine Release Syndrome Management. In addition, the European regionis projected to grow rapidly in the global Cytokine Release Syndrome Management market due to the growing acceptance of immunotherapy for treating solid tumours.
Recent Developments:
- In October 2024, GSK plc reported favourable primary outcomes from the phase III clinical studies ANCHOR-1 and ANCHOR-2, which evaluated the efficacy and safety of depemokimab compared to placebo in adults with chronic rhinosinusitis with nasal polyps (CRSwNP). The comprehensive findings of ANCHOR-1 and ANCHOR-2 will be disclosed at an imminent scientific symposium.
Cytokine Release Syndrome Management Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 23.1 Bn |
|
Revenue Forecast In 2031 |
USD 36.8 Bn |
|
Growth Rate CAGR |
CAGR of 6.2% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
Cytokine Type, Therapeutic Application, Biomarker Type, Route Of Administration, And End User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
F.Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Novartis AG, Sanofi S.A, Pfizer Inc., Bayer AG, Biocon, AbbVie Inc., Johnson & Johnson Private Limited, Incyte Corporation, Swedish Orphan Biovitrum, and Genentech. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
